Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.20.760382

Patient-Centric Development of a Low-Volume, Low-Viscosity, Once Every 4 Weeks (Q4W) Autoinjector Combination Product for Povetacicept

Lucas, J.·Floyd, J. A.·Hickey, E.·Perez-Lopes, C.·Lehane, R.·Chawla, M.·Salema, M.·Graffius, G.
View original source ↗Export metadata ↓

Abstract

Biologic therapies delivered subcutaneously (SC) are increasingly moving toward at-home self-administration using drug-device combination products. This shift places greater emphasis on the patient experience, and factors such as dose volume, injection time, dosing frequency, viscosity, injection force, and ease of use can affect treatment burden. This article focuses on the impact of balancing high protein concentration with low viscosity during drug product formulation development for an improved patient experience for povetacicept, an investigational, subcutaneously administered dual B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) inhibitor being developed for the treatment of multiple kidney diseases, including IgA nephropathy (IgAN). For povetacicept, formulation and device considerations were integrated throughout development. Studies evaluated protein concentration, dose volume, viscosity, injection force, injection time, and usability, in addition to standard stability, to develop a low-volume Q4W autoinjector. The selected 175 mg/mL formulation delivers an 80 mg dose in 0.46 mL. The viscosity was no more than 10 cP at 15-25{degrees}C and in a 1 mL prefilled syringe, the average glide force was 6 N, and the injection time at a constant force of 20 N was < 2 seconds. The same prefilled syringe was incorporated into an autoinjector with an injection time of less than 2 seconds in air. We conducted a limited assessment of an approved treatment for IgAN (Voyxact) administered via prefilled syringe (PFS) for effects of viscosity, fill volume and syringe configuration under the same experimental conditions. The viscosity at room temperature was 16 cP, with an average glide force of 27N and injection time of 19 seconds for the 2 mL dose. In conclusion, povetacicept was designed to support convenient and user-friendly at-home self-administration through Q4W dosing, a low injection volume, a low viscosity formulation, rapid delivery, and an easy-to-use autoinjector. This integrated formulation and device development approach demonstrates how patient-centric considerations can be incorporated in combination product development. Together, these attributes have the potential to reduce the practical burden associated with repeated, long-term treatment for IgAN patients.

Explore related subjects

bioengineeringPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lucas, J., Floyd, J. A., Hickey, E., Perez-Lopes, C., Lehane, R., Chawla, M., Salema, M., Graffius, G.. 2026-10-21. Patient-Centric Development of a Low-Volume, Low-Viscosity, Once Every 4 Weeks (Q4W) Autoinjector Combination Product for Povetacicept. https://doi.org/10.64898/2026.10.20.760382

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Mesoscale Soft Robotics for Mechanically Perturbing and Functionally Monitoring Responses in Human Organoids

Human organoids represent promising models for studies of significance to the biology and medical communities. Of the existing approaches for monitoring organoids, none offers the ability to apply programmable mechanical forces while simultaneously recording multi-modal physiological responses, of relevance to phenomena spanning from traumatic brain injuries to cardiac rhythm disorders. Here, we present a mesoscale soft robotic organoid interface that enables programmable delivery of forces to organoids of diverse shapes, and to map electrophysiological activity and mechanical responses. The platform combines actuation elements with integrated sensors for quantitative measurement and control. Studies using this technology reveal that spheroidal cortical organoids exhibit distinct responses to mechanical trauma, including silencing, recovery, and changes in neuronal firing patterns. Additional experiments on cardiac ring tissues demonstrate that sustained stretching induces beat-to-beat rhythm variability and altered conduction. The results establish a framework for investigating force-triggered transitions between physiological and disease-like states in human tissue models.

bioengineering↗
bioRxiv2026

Few-shot regulatory sequence design with a genomic language model

A central challenge in generative biology is translating knowledge learned from natural sequences and experiments into designs with desired functions. In-context learning (ICL) is an emergent capability of large language models that allows them to adapt to new tasks from a few examples without additional training, enabling these models to become general-purpose learners. Here, we show that the genome language model, Evo 2, exhibits generative ICL in biological sequence design. Prompting with just tens of examples conditions Evo 2 to generate novel and diverse regulatory DNA sequences without any additional training. Mechanistic analysis suggests that genomic ICL may originate from induction, similar to phenomena observed in natural language. Reinforcement learning leveraging sequence-to-function models as experiment-derived rewards further strengthens ICL. We first validate this approach by generating enhancers that drive cell-type-specific gene expression in three human cell lines. Extending this approach in vivo, enhancers designed using human regulatory element data selectively label layer 5 extratelencephalic neurons in the mouse cortex with high specificity and stronger activity than existing enhancers. Our study provides evidence of emergent properties in genomic sequence models and introduces a promising approach for improving functional conditioning in generative biology.

bioengineering↗
bioRxiv2026

IOP-independent treatment for neurodegeneration in glaucoma using optimized ROS-scavenging microparticles for sustained release of erythropoietin

Glaucoma is a slow-progressing neurodegenerative disease of the optic projection to the brain and a leading cause of blindness worldwide. Current treatments are targeted towards lowering intraocular pressure (IOP), the only known, modifiable risk factor; however, this strategy is ineffective in many patients. An early hallmark of glaucomatous neurodegeneration is increased reactive oxygen species (ROS), representing an alternative opportunity for intervention to halt or slow disease progression. In this work, we optimize a ROS-scavenging copolymer, poly(propylene sulfide-co-ethylene sulfide) (PPSES), for formulation of size-controlled, stabilized, antioxidant microparticles (MPs) for sustained release of the protein erythropoietin (EPO). EPO promotes biological antioxidant defense via activation of NRF2-mediated transcription of antioxidant genes. This MP system overcomes the short half-life of EPO and leverages the combined benefits of bioactive EPO with long-lasting, inherently antioxidant PPSES MPs. The lead EPO-MP formulation preserves neurons in both mouse and non-human primate models of glaucoma through suppression of oxidative stress and optic nerve degeneration. EPO-loaded PPSES MPs represent a translationally relevant therapy for long-term management of glaucoma independent of IOP.

bioengineering↗